CHE

Healthcare services company Chemed Corporation (NYSE:CHE) announced better-than-expected revenue in Q3 2026, with sales up 10.6% year on year to $690.9 million. Its non-GAAP profit of $6.75 per share was 4.9% above analysts’ consensus estimates.

Chemed (CHE) is back in focus after a strong third quarter, with higher profit, rising earnings per share and a guidance raise that, together with an analyst upgrade, has stirred fresh interest in the stock.

Chemed’s third quarter saw positive market reaction, with results surpassing Wall Street’s revenue and non-GAAP profit expectations.

Chemed’s updated fair value estimate has shifted from US$571.60 to US$592.60, a change of about 3.7% in the latest analyst work.

Chemed (NYSE:CHE) reported higher third-quarter revenue and adjusted earnings as growth at its VITAS hospice business offset margin pressure at Roto-Rooter from customer-acquisition and fuel costs.

CINCINNATI (AP) — CINCINNATI (AP) — Chemed Corp. (CHE) on Tuesday reported profit of $71.

Labcorp raised its FY2026 revenue and earnings forecasts following a Q3 beat, while Chemed attracted an analyst upgrade after its VITAS business drove Q3 earnings growth.

VITAS revenue surged 12.2% while Roto-Rooter margins compressed from higher costs.

Investing.com -- Chemed Corp (NYSE:CHE) shares jumped 8.7% in Wednesday trade after Jefferies upgraded the healthcare and maintenance conglomerate to Buy from Hold, arguing that the company is poised to regain its premium valuation as operating volatility…

Moby summary of Chemed Corporation's Q3 2026 earnings call